




RealRate

PHARMACEUTICAL 2020

Concert Pharmaceuticals INC
Rank 141 of 363

CoNCERT



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Concert Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Concert Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Concert Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 278%, being 40% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	116,855
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,268
Liabilities, Non-Current	18,746
Other Assets	12,863
Other Compr. Net Income	106
Other Expenses	0
Other Liabilities	0
Other Net Income	837
Other Revenues	1,089
Property and Equipment	7,753
Research and Development	59,816
Selling, General and Administrative Expense	20,276

Output Variable	Value in 1000 USD
Assets	137,471
Liabilities	36,014
Expenses	80,092
Revenues	1,089
Stockholders Equity	101,457
Net Income	-78,166
Comprehensive Net Income	-78,113
BaseVar	127,804
ECR before LimitedLiability	165%
Economic Capital Ratio	278%